Refined mapping of the gene for thiamine-responsive megaloblastic anemia syndrome and evidence for genetic homogeneity
- PMID: 9856490
- DOI: 10.1007/s004390050850
Refined mapping of the gene for thiamine-responsive megaloblastic anemia syndrome and evidence for genetic homogeneity
Abstract
Thiamine-responsive megaloblastic anemia (TRMA, also known as Rogers syndrome, OMIM 249270) is a rare autosomal recessive disorder characterized by a triad of megaloblastic anemia, diabetes mellitus, and sensorineural deafness. Patients respond, to varying degrees, to treatment with megadoses of thiamine. We have recently shown genetic linkage of the TRMA gene to a 16-centimorgan (cM) region on 1q23.2-1q23.3 based on the analysis of four large, inbred families of Alaskan, Italian, and Israeli-Arab origin. Here we narrow the TRMA interval down to 4 cM based on genetic recombination, homozygosity mapping, and linkage disequilibrium (highest LOD score of 12.5 at D1S2799, at a recombination fraction of 0). We provide further evidence that the TRMA gene is located in this region and confirm the homogeneity of the disease. In this analysis, we genotyped seven additional families of diverse ethnic origin (Pakistani, Indian, Italian, Brazilian, and Japanese), and analyzed additional markers in two previously reported families showing evidence of linkage disequilibrium in a large area of their haplotypes. The multi-system manifestations of TRMA suggest that thiamine has a pivotal role in a multiplicity of physiological processes. Mapping the TRMA gene and understanding the molecular basis of the disease might, thus, shed light on the role of thiamine in common disorders such as deafness, anemia, and diabetes.
Similar articles
-
Localization of the gene for thiamine-responsive megaloblastic anemia syndrome, on the long arm of chromosome 1, by homozygosity mapping.Am J Hum Genet. 1997 Dec;61(6):1335-41. doi: 10.1086/301642. Am J Hum Genet. 1997. PMID: 9399900 Free PMC article.
-
Localization of the thiamine-responsive megaloblastic anemia syndrome locus to a 1.4-cM region of 1q23.Mol Genet Metab. 1999 Mar;66(3):193-8. doi: 10.1006/mgme.1998.2799. Mol Genet Metab. 1999. PMID: 10066388
-
Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness.Nat Genet. 1999 Jul;22(3):300-4. doi: 10.1038/10372. Nat Genet. 1999. PMID: 10391221
-
Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome.Pediatr Cardiol. 2003 Sep-Oct;24(5):476-81. doi: 10.1007/s00246-002-0215-3. Pediatr Cardiol. 2003. PMID: 14627317 Review.
-
Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia.Pediatr Diabetes. 2012 Jun;13(4):314-21. doi: 10.1111/j.1399-5448.2012.00855.x. Epub 2012 Feb 27. Pediatr Diabetes. 2012. PMID: 22369132 Review.
Cited by
-
Defective high-affinity thiamine transporter leads to cell death in thiamine-responsive megaloblastic anemia syndrome fibroblasts.J Clin Invest. 1999 Mar;103(5):723-9. doi: 10.1172/JCI3895. J Clin Invest. 1999. PMID: 10074490 Free PMC article.
-
A novel mutation in the thiamine responsive megaloblastic anaemia gene SLC19A2 in a patient with deficiency of respiratory chain complex I.J Med Genet. 2000 Sep;37(9):669-73. doi: 10.1136/jmg.37.9.669. J Med Genet. 2000. PMID: 10978358 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical